

# Non-clinical development of C2-558, a SOS1 inhibitor, for the treatment of patients with KRAS mutant solid tumors

Cyrus Therapeutics



ONCOLOGY	Preclinical
Product Type	Small Molecules
Indication	Solid Tumor
Target	SOS1
MoA(Mechanism of Action)	C2-558 binds to SOS1 and disrupts the protein-protein interaction of SOS1 and RAS
Competitiveness	<ul style="list-style-type: none"> <li>• C2-558 exhibits strong inhibitory activities against a broad spectrum of wild-type and mutant RAS proteins as a pan-RAS inhibitor.</li> <li>• The combined oral administration of C2-558 with either sotorasib or osimertinib demonstrates significantly improved antitumor efficacy compared to using each individual agent alone in mouse xenograft models.</li> <li>• C2-558 has excellent oral bioavailability, providing good exposure while maintaining low plasma clearance across different species, alongside high unbound fractions.</li> </ul>
Development Stage	Preclinical
Route of Administration	Oral Administration